Sen. Burr Worries Rising User Fees Helping US FDA Evade Congressional Oversight
Burr Had Raised Questions During 2017 Reauthorization Cycles
Burr wants more FDA accountability in the new user fee agreements and questions whether they benefit patients. Generic approval modifications get attention at hearing.
